Sat.Mar 16, 2024 - Fri.Mar 22, 2024

article thumbnail

Vaccines to Watch in 2024

Drug Topics

Moderna, Merck, and Pfizer-BioNTech are leading the charge with new vaccines for respiratory viruses in development.

Vaccines 199
article thumbnail

Patient centricity for tailor-made healthcare

European Pharmaceutical Review

Can you tell us a bit about yourself and your role at Pfizer? I’m a pharmacist with an MBA and PhD. My PhD thesis is about considerations in the production and purchasing of drugs. I joined Pfizer in January 2023 as a health access specialist, after working at Clalit Health Services in Israel for almost 20 years. At Clalit, which is the second largest healthcare provider in the world, I worked in several management positions and gained a broad understanding of the needs and constraints of a heal

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Adaptation Is the Key to Success

Drug Topics

Farmers and welders have adapted to work with the current times. Pharmacists should consider adapting their profession as well.

181
181
article thumbnail

Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

Pharmacy Times

Michael Singel, PharmD, discusses the role of pharmacists in the operationalization of bispecifics to treat multiple myeloma, including the creation of treatment plans and standard of care order sets.

121
121
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

3D printing and personalised medicines: embracing innovative technologies

Hospital Pharmacy Europe

Supporting the successful compounding of drugs with 3D printing processes has the potential to not only fulfil unmet patient needs but also drive efficiencies in hospital pharmacies. Ian Soulairol from the Institut Charles Gerhardt Montpellier at Montpellier University and pharmacist at the Department of Pharmacy of Nîmes University Hospital in France shares insights into how this technology is evolving and what it means for clinical practice now and in the future. 3D printing, or additive manuf

Hospitals 111
article thumbnail

FDA authorizes new drug to protect immune compromised from Covid-19

STAT

The Food and Drug Administration on Friday authorized a new antibody to protect immunocompromised individuals against Covid-19.  The drug, known as Pemgarda and marketed by the biotech Invivyd, is the first such drug to become available since the agency pulled AstraZeneca’s Evusheld off the market in January 2023. New Omicron variants had rendered Evusheld ineffective.

More Trending

article thumbnail

Study: Researchers Identify 25 Air Pollutants Associated With Asthma Symptoms

Pharmacy Times

Investigators found that 1,1,1 trichloroethane; 2-nitropropane; and 2,4,6 trichlorophenol were significantly associated with asthma symptoms for 3 exposure periods.

164
164
article thumbnail

Providers 'wasted' $10.6B in 2022 overturning claims denials, survey finds

Fierce Healthcare

More than 100 provider organizations want the Centers for Medicare & Medicaid Services (CMS) to take a tougher stance on Medicare Advantage (MA) plans’ practices following an industry survey es | Providers spent nearly $20 billion in 2022 pursuing delays and denials across all payer types, yet those efforts are substantially more costly on average when dealing with private plans, hundreds of hospitals and health systems told Premier in a recent survey.

Hospitals 144
article thumbnail

STAT+: Gene-edited pig kidney transplanted into a living patient for the first time

STAT

In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday that, for the first time, it had transplanted a kidney from a CRISPR gene-edited pig into a living patient. Surgeons performed the milestone procedure over four hours on Saturday, March 16, without complications. As of Thursday morning, the organ recipient, a 62-year-old man named Richard Slayman, was “recovering well” and expected to be discharged soon, the hospital said in a

Hospitals 145
article thumbnail

Psilocybin Side Effects Found to be Tolerable, Resolve Within 2 Days

Drug Topics

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

197
197
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

FDA Expands Label for Bempedoic Acid to Reduce Cardiovascular Risk, With or Without Statins

Pharmacy Times

Bempedoic acid (Nexletol; Esperion) and bempedoic acid and ezetimibe (Nexlizet; Esperion) are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.

Labelling 152
article thumbnail

Google's healthcare AI ambitions: New model for personal health coaching and next steps for gen AI

Fierce Healthcare

Google is doubling down on its ambitions for healthcare AI by exploring how generative AI can help clinicians in medical decision-making, understand lab and imaging information and provide con | Google is hyper-focused on generative AI in healthcare, pushing forward research to advance gen AI capabilities that can help clinicians in medical decision-making, understand lab and imaging information and provide consumers with personalized health insights based on their wearable data.

144
144
article thumbnail

STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives

STAT

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures.

145
145
article thumbnail

Novavax COVID-19 Vaccine Shows Lasting Protection Against Delta Variant

Drug Topics

The biotechnology company’s recombinant spike protein-based vaccine demonstrated an efficacy of 88% after 40 days, 82% after 120 days, and 77% after 180 days during the PREVENT-19 trial.

Vaccines 232
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

FDA Issues Paper on the Responsible Use of Artificial Intelligence in Medical Research

Pharmacy Times

The agency will focus on collaboration to protect public health; advancing regulatory approaches; developing standards, guidelines, and best practices; and supporting research that evaluates and monitors AI performance.

FDA 145
article thumbnail

SXSW24: Better communication, collaboration, reimbursement needed to improve cancer care

Fierce Healthcare

Uncomfortable waiting rooms. Revealing hospital gowns. Confusing insurance. Exhausting travel between appointments. | Oncology was a major focus at this year’s SXSW conference. Across multiple sessions, clinicians and patient advocates called for better access to specialty care, more thoughtful communication with patients and continued collaboration across stakeholders.

article thumbnail

A study says intermittent fasting is making people drop dead. Oh, come on

STAT

The news is everywhere in my social news feeds this morning: A popular fad diet is apparently lethal, scientific research says. Specifically, a study found that caloric restriction, also known as intermittent fasting, has a 91% risk of death due to cardiovascular disease. Except scientific research doesn’t say that — and not only should you not be worried about this study, you shouldn’t be wasting brain glucose thinking about it.

145
145
article thumbnail

Local Pharmacy Access in the United States Significantly Lower in Rural Areas

Drug Topics

Researchers collected data to measure inequities in pharmacy access across the country.

211
211
article thumbnail

As Cannabis Use Increases, Pharmacists Must Be Prepared to Counsel Patients

Pharmacy Times

As more states have legalized cannabis use—both medicinal and recreational—Sera said pharmacists’ roles in counseling will become even more important.

153
153
article thumbnail

Nvidia inks tie-ups with Abridge, GE HealthCare and Microsoft as it expands its footprint in healthcare AI

Fierce Healthcare

Chipmaker Nvidia sees big opportunities in healthcare AI and this week it launched more than two dozen new gen AI-powered microservices. | The global computing powerhouse inked collaborations with Abridge, Microsoft, GE HealthCare and Hippocratic AI to to expand its generative AI capabilities into healthcare and life sciences.

133
133
article thumbnail

Opinion: The evidence is clear: A liquid-only diet before a colonoscopy is unnecessary

STAT

Since colorectal cancer is on the rise in people younger than age 50, national guidelines have recently pushed the starting age for colorectal cancer screening down to 45. We need to spread the word. Yet we specialists continue to provide outdated and disproven recommendations on colonoscopy bowel preparation that make the process more difficult for the millions of patients who undergo colonoscopy every year: We tell them to adopt a clear liquid diet the day before their procedure.

145
145
article thumbnail

FDA Approves Rilpivirine For Treatment of HIV-1 in Pediatric Patients

Drug Topics

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

FDA 199
article thumbnail

Navigating Cannabis in Pharmacy Practice: State Legislation and Contraindications for Patient Use

Pharmacy Times

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

138
138
article thumbnail

Hippocratic AI banks $53M backed by General Catalyst, a16z, Memorial Hermann, UHS and other health systems

Fierce Healthcare

Launched out of stealth about a year ago, Hippocratic AI launched its first generative AI product and pocketed $53 million in series A funding, the startup announced Monday. | Launched out of stealth about a year ago, Hippocratic AI launched its first generative AI product and pocketed $53 million in series A funding. The fresh funding boosts the company's valuation to $500 million.

134
134
article thumbnail

Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’

STAT

Early data regarding the use of GLP-1 medications like Ozempic and Wegovy to treat addiction is “very, very, exciting,” Nora Volkow, the director of the National Institute on Drug Abuse, said Thursday. But even as she expressed enthusiasm for the new drugs’ potential, Volkow criticized pharmaceutical companies for neglecting a moral imperative to develop new addiction treatments — but acknowledged that the health system more broadly doesn’t incentivize drug com

article thumbnail

Veterans Reported Loss of Everyday Functioning After COVID-19 Pandemic

Drug Topics

Researchers aimed to address the adverse effects of veterans with COVID-19 diagnoses 18 months after infections were documented.

article thumbnail

FDA Advisory Committee Votes in Favor of Ide-Cel for Adult Patients With Multiple Myeloma

Pharmacy Times

The decision to vote in favor of idecabtagene vicleucel comes after positive phase 3 trial results demonstrating its efficacy compared with standard regimens.

FDA 144
article thumbnail

Google Health, Stanford Medicine unveil open-access dataset of diverse dermatology images

Fierce Healthcare

Google Health unveiled an open-access dataset of real-world dermatology images in partnership with Stanford Medicine. | Thousands of people contributed their images of skin, hair and nail conditions to the Skin Condition Image Network (SCIN) for a diverse dataset reflecting various skin tones, ages, settings and condition severities.

134
134
article thumbnail

STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves.

article thumbnail

BioNTech's shares tumble—again—amid continued COVID vaccine sales slide

Fierce Pharma

Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations.

Vaccines 133
article thumbnail

Celltrion USA Submits Biologics License Application for CT-P39, a Biosimilar to Xolair

Pharmacy Times

The BLA includes all indications for Xolair, including asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergy, and chronic spontaneous urticaria.

132
132
article thumbnail

CDC releases field-tested guidance for hospital CEOs tackling their workers' mental health

Fierce Healthcare

The Centers for Disease Control and Prevention (CDC)’s campaign against healthcare worker burnout took a step forward this week with the release of a new instructional guide for executive-level hos | The free resource was developed alongside the Dr. Lorna Breen Heroes' Foundation and informed by a six-month, six-hospital pilot across CommonSpirit Health facilities.

Hospitals 134
article thumbnail

STAT+: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds

STAT

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

141
141
article thumbnail

AI in Drug Discovery: Day One

pharmaphorum

There is no denying that artificial intelligence (AI) has captured the imagination of innovators working across the pharmaceutical sector. The drug discovery space is no different, with myriad applications promising to revolutionise the way that researchers and sponsors approach identifying and progressing new drug candidates.

125
125